102 related articles for article (PubMed ID: 24522037)
1. Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Richie JP
J Urol; 2014 Mar; 191(3):659. PubMed ID: 24522037
[No Abstract] [Full Text] [Related]
2. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
3. [Value of tumor marker positivity in germinal non-seminomatous tumors of the testis].
Bassetto MA; Franceschi T; Lenotti M; Pancheri F; Zaninelli M; Corgnati A; Cetto GL
J Nucl Med Allied Sci; 1990; 34(4 Suppl):89-90. PubMed ID: 1709212
[No Abstract] [Full Text] [Related]
4. Monitoring of patients with non-seminomatous germ cell tumors of the testis by determination of alpha-fetoprotein and beta-human chorionic gonadotropin levels and by computed tomography.
Kausitz J; Ondrus D; Belan V; Matoska J
Neoplasma; 1992; 39(6):357-61. PubMed ID: 1283444
[TBL] [Abstract][Full Text] [Related]
5. The use of serum tumor markers in the management of patients with malignancy.
Markman M
J Cancer Res Clin Oncol; 1993; 119(11):635-6. PubMed ID: 7688748
[No Abstract] [Full Text] [Related]
6. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
Fottner C; Sattarova S; Hoffmann K; Spöttl G; Weber MM
Eur J Endocrinol; 2008 Sep; 159(3):317-27. PubMed ID: 18524796
[TBL] [Abstract][Full Text] [Related]
7. Metastatic non-seminomatous germ cell tumour and dermatomyositis.
Barker RA; Currie DC; Horwich A; Spiro SG
Postgrad Med J; 1990 Jan; 66(771):59-60. PubMed ID: 1693426
[TBL] [Abstract][Full Text] [Related]
8. TRA-1-60: a new serum marker in patients with germ-cell tumors.
Marrink J; Andrews PW; van Brummen PJ; de Jong HJ; Sleijfer DT; Schraffordt Koops H; Oosterhuis JW
Int J Cancer; 1991 Sep; 49(3):368-72. PubMed ID: 1717384
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in metastatic disease.
Droz JP; Kramar A; Rey A
Semin Oncol; 1992 Apr; 19(2):181-9. PubMed ID: 1372760
[No Abstract] [Full Text] [Related]
10. Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective.
Skinner DG; Scardino PT
Trans Am Assoc Genitourin Surg; 1979; 71():31-5. PubMed ID: 94715
[No Abstract] [Full Text] [Related]
11. Drug-resistance patterns assessed from tumor marker analysis.
Carl J
J Natl Cancer Inst; 1989 Nov; 81(21):1631-9. PubMed ID: 2477557
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
Mego M; Rejlekova K; Reckova M; Sycova-Mila Z; Obertova J; Rajec J; Mardiak J
Neoplasma; 2009; 56(5):398-403. PubMed ID: 19580341
[TBL] [Abstract][Full Text] [Related]
14. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
15. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy.
Hoskin P; Dilly S; Easton D; Horwich A; Hendry W; Peckham MJ
J Clin Oncol; 1986 Jul; 4(7):1031-6. PubMed ID: 2425060
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and immunologic diagnosis of cancer. Germ cell tumors.
Schwartz MK
Tumour Biol; 1987; 8(2-3):106-8. PubMed ID: 2452467
[No Abstract] [Full Text] [Related]
18. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
19. [Primary mediastinal germ cell tumor with marked elevation of HCG and alpha-fetoprotein].
Nakagawa Y; Kuwahara O; Nakaoka K; Dohi H; Hanada M
Nihon Kyobu Geka Gakkai Zasshi; 1987 Mar; 35(3):381-6. PubMed ID: 2439616
[No Abstract] [Full Text] [Related]
20. Germ-cell tumors of the testis: improved results in a prospective study using combined modality therapy and biochemical tumor markers.
Scardino PT; Skinner DG
Surgery; 1979 Jul; 86(1):86-93. PubMed ID: 88077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
